pharmaphorum
MARCH 31, 2021
Germany and Canada have both slapped restrictions on the AstraZeneca vaccine, recommending its use only in older patients, because of concerns over a link with blood clots. The moves come after the country’s medicines regulator found 31 cases of a rare type of blood clot known as cerebral venous sinus thrombosis (CVST) in people who had received the vaccine produced by AZ.
Druggist
APRIL 1, 2021
Amlodipine is one of the most commonly prescribed drugs in the UK and the most prescribed high blood pressure ( BP ) medication. When patients are diagnosed with high blood pressure and a drug is recommended, amlodipine may be the first choice, but not always. Taking any drugs comes with a risk of side effects, with amlodipine associated with few common side effects.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Outsourcing Pharma
MARCH 30, 2021
A couple of new developments to report in relation to Merck, known as MSD outside the US and Canada: the first being the rejection by the US FDA of the companyâs application to use its anti-PD-1 therapy, Keytruda, in certain breast cancer patients.
Pharma Marketing Network
MARCH 30, 2021
Until the COVID-19 pandemic struck the world in early 2020, pharma had been pretty resistant to the idea of involving the end-customer, or the patient, into their business models. COVID-19 not only left pharma no choice but to take this challenge head on, it also paved the way for pharma to build extensive awareness of their brands, as several big names have been in the spotlight in the fight against COVID-19.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
MARCH 30, 2021
The government has continued its shake-up of UK health authorities with the creation of the Office of Health Promotion (OHP), which will focus on issues like obesity, mental and sexual health, and promoting physical activity. . The OHP will take over the health improvement remit currently the responsibility of Public Health England (PHE), and will “lead national efforts to improve and level up the public’s health,” according to the government.
Fuld
MARCH 30, 2021
Christian Schena brings prolific relationship-building, sales consulting, lead generation, and business development experience to the firm. Boston, Mass. March 30, 2021 — Fuld + Company, a global competitive strategy consultancy, today announced the recent appointment of Christian Schena as Senior Director of Sales. In this role, he will leverage decades of experience in the sales consulting space to develop customized solutions for clients of Fuld + Company that are critical for market competit
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharma Marketing Network
APRIL 2, 2021
The AI in Healthcare Virtual Summit focused on AI methods and tools that are set to transform healthcare, medicine, and diagnostics along with the latest applications within the industry. . Here are some key sessions during the summit that discussed machine learning for antibiotic discovery, creating personalized neuro medicine using AI and brain modelling, and deep learning for biomedical imaging.
pharmaphorum
MARCH 29, 2021
Akili has published data backing the efficacy of its childhood attention-deficit hyperactivity disorder (ADHD) video game therapy EndeavorRx in the peer-review journal Nature Digital Medicine. . The results come from the STARS-Adjunct trial, an open-label study of EndeavorRx (AKL-T01) that supported approval of the app and video game combination in the US and Europe last year.
Pharma Mirror
MARCH 31, 2021
Azelis, an innovation service provider, is excited to release its sustainability strategy, ‘Action 2025’, reinforcing its commitment to become the world-leading provider of sustainable solutions and services in the specialty chemicals and food ingredients distribution industry. Through its sustainability program and strategy, Azelis wants to turn the sustainability aspirations of its principals and customers into innovative sustainable solutions.
Outsourcing Pharma
APRIL 1, 2021
The advanced biotech analysis company is harnessing the power of a formidable supercomputer to discover potential treatments for the virus and mutations.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharma Marketing Network
MARCH 31, 2021
The virtual NextGen Pharma Content Summit on March 23-24, 2021 focused on the importance of creating personalized and genuine content for their customers in the right place and at the right time. Sessions throughout the summit touched on the many ways that companies can convey the right message to their customers. By creating personalized and meaningful messages to customers, companies can build trust and earn brand loyalty. .
pharmaphorum
APRIL 1, 2021
AI simulated cell company Turbine is just one of many digital drug discovery firms on the rise in Hungary. We speak to the company’s CEO and co-founder, Szabolcs Nagy, to find out why moving beyond traditional biotech drug development is a good fit for the country’s ecosystem. Hungarian company, Turbine, is taking an alternative approach to the standard biotech drug development model with its AI-based simulated cell technology, which helps the bulk of preclinical drug discovery take place digita
Pharma Mirror
MARCH 31, 2021
Informa Markets is launching an annual dedicated online platform for pharma in May (17-28th), CPhI Discover – designed to encourage suppliers and customers to source, meet and discover – providing the industry with a new synergistic offering to sit alongside CPhI’s portfolio of in person events. In the last year, the pharma industry has adapted its approach to meeting new partners and existing customers, with wider pools of suppliers now needed, putting greater pressure on resources to find and
Outsourcing Pharma
MARCH 29, 2021
A representative of the rare-disease specialist firm outlines the unique obstacles of orphan CNS disease research, and how professionals can overcome them.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Med Ed 101
MARCH 28, 2021
Sacubitril/valsartan (ARNI) is getting more attention in the guidelines with regards to its use in heart failure (specifically HFrEF). Many patients are already on an ACE and making the transition from an ACE inhibitor to an ARNI is likely something you will come across. In clinical practice, there is a significant risk for angioedema when […].
pharmaphorum
MARCH 30, 2021
Two antibodies targeting different parts of the COVID-19 virus spike protein, from Eli Lilly and GlaxoSmithKline/Vir Biotech, can cut viral load dramatically within a week. . The BLAZE-4 trial found that co-administration of Lilly’s bamlanivimab – already granted emergency approval as a COVID-19 treatment – and GSK/Vir’s experimental antibody VIR-7831 reduced virus levels by 70% after seven days compared to placebo in people with mild or moderate COVID-19 symptoms.
Pharma Times
MARCH 30, 2021
Kinase inhibitor authorised to treat advanced bile duct cancer patients with a FGFR2 fusion or rearrangement
Outsourcing Pharma
MARCH 29, 2021
An expert speaking at the April 6 Clinical Development Innovations event will discuss an app that matches patients with clinical research opportunities.
Birth Control Pharmacist
MARCH 29, 2021
I recently had the opportunity to attend the Sex & Gender 101 webinar designed to help anyone in the healthcare field learn more about creating trans inclusive care. It is crucial to create an environment that is inclusive because trans people – especially trans people of color – face many barriers to healthcare. We have all had doctor’s appointments where we were required to fill out a form and check one of two boxes to describe our gender: male or female.
pharmaphorum
MARCH 31, 2021
Novartis has added to its pipeline of radiopharmaceuticals pipeline once again, licensing a series of agents from iTheranostics that can be used to show where tumours are located in the body. . The diagnostic imaging agents all target fibroblast activation protein (FAP), a molecule that is only expressed at low levels on healthy cells but is found much more abundantly in solid tumours.
Pharma Times
MARCH 31, 2021
Funding for effective, 'less risky' treatments extended until summer 2021
Outsourcing Pharma
MARCH 29, 2021
According to a Veeva Systems survey, contract research organizations are working to ensure clinical trials keep going during the COVID-19 era and beyond.
pharmaphorum
MARCH 31, 2021
In the latest episode of the podcast Dominic Tyer speaks with GlaxoSmithKline’s Philip Cruz about the discovery and commercialisation of new vaccines in the light of the pandemic. Philip who is vaccines medical director for the UK and Ireland, and a paediatrician by training, tackles the clear pre- and post-COVID differentiation seen in approaches to vaccines.
pharmaphorum
MARCH 29, 2021
The way NICE reviews new medicines is about to go through its biggest change in years – but what do the proposals mean for the future of drug development in the UK? Amanda Barrell spoke to Dr Paul Catchpole, director of value and access policy at the ABPI, to find out. From COVID-19 and Brexit, to the emergence of patient-centric drug development and personalised medicine, the life sciences sector has experienced a complete transformation in recent years.
pharmaphorum
APRIL 1, 2021
The head of the EMA has reiterated that there is no evidence to limit the use of AstraZeneca’s COVID-19 vaccine in any age group, after Germany and Canada imposed restrictions in younger patients. . “Our position has not changed” from a safety update two weeks ago, said Emer Cooke at an EMA press conference today. “According to the current scientific knowledge, there is no evidence that would support restricting the use of this vaccine in any population.” She added
pharmaphorum
MARCH 29, 2021
The EU looks set to approve emergency use of a third antibody therapy for COVID-19 after its human medicines committee backed use of Celltrion’s regdanvimab at its March meeting. . Regdanvimab (CT-P59) – which is currently under a rolling review at the EMA – can be used for the treatment of COVID-19 in adults who don’t need oxygen therapy but are at high risk of progressing to severe COVID-19, according to the CHMP.
pharmaphorum
MARCH 30, 2021
All Nippon Airways (ANA) has begun a trial of its CommonPass app showing a traveller’s COVID-19 status at Tokyo’s Haneda Airport. It’s part of efforts by the global travel industry to make cross-border travel easier and safer and is one of several digital health passports being trialled around the world. The idea is to provide an accurate but fast way of ensuring passengers are safe to travel and prevent the spread of COVID-19 and potential variants.
pharmaphorum
APRIL 1, 2021
Incentivising people with KPI-linked bonuses is nothing new. Especially in commercial roles it has long been standard. The issue with KPIs is they can be very ineffective. If clearly defined they will get you results, but if not, they can just reinforce the wrong behaviours. The difficulty is to define the right ones. Bottomline is that KPI-based incentives will hardly ever create the behaviour that you want and in some of the worst examples have caused a disaster like the financial crisis in 20
pharmaphorum
MARCH 29, 2021
VMLY&Rx, a comms agency dedicated to prescription pharmaceutical companies who are researching and developing breakthrough therapies, has hired Nichole Davies as global chief strategy officer. . Davies will lead a new global strategic practice to deliver and enable connected health strategies for clients. The team comprises specialists across a wide range of strategic expertise including brand, activation, innovation and medical.
pharmaphorum
MARCH 29, 2021
The FDA has approved Bristol-Myers Squibb’s Abecma (idecabtagene vicleucel) for multiple myeloma, the first cell therapy to treat the disease. Abecma’s review was delayed after the FDA rejected a first filing in May last year, but it’s hoped that the drug could be a significant step forward in the treatment of this incurable condition. It is a CAR-T (chimeric antigen receptor T-cell) therapy, where a patient’s own T-cells are harvested, genetically modified and then reinjected to fight the cance
pharmaphorum
MARCH 30, 2021
Pharma is moving to a new era of radically new therapies, presenting unexpected and difficult challenges. Such interventions take the need for robust value claims to a completely different level, with important implications for the evidence companies need to collect, and how they collect and communicate it. Chris Gray leads Innovation and Ventures for Adelphi’s Healthcare Communications agencies, whose long-running Renaissance series has been discussing the implications of ‘ transformational va
pharmaphorum
APRIL 1, 2021
The UK’s cost-effectiveness agency NICE has recommended that Sobi’s Kineret can be used to treat NHS patients with Still’s disease, a rare form of arthritis affecting children and adults. The final guidance concludes that interleukin-1 receptor antagonist Kineret (anakinra) can be used as a treatment for two forms of Still’s, namely systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD).
pharmaphorum
MARCH 29, 2021
With the focus on COVID-19 over the last year it’s easy to forget another deadly pandemic caused by antimicrobial resistance (AMR), which could lead to the most innocuous of infections becoming life threatening. The Novo Holding REPAIR Impact Fund is hoping to change this with its latest call for investment proposals to fight AMR. While there have been huge strides in treatments for cancer and other diseases in the last few decades, research into new antibiotics has been almost stagnant as big p
pharmaphorum
MARCH 31, 2021
Amgen has announced its second acquisition in the space of a month, snapping up Rodeo Therapeutics and its potential tissue repair drugs in a deal worth up to $721 million. Rodeo is a privately held biopharmaceutical company based in Seattle that develops small-molecule therapies designed to promote regeneration and repair of several tissues and could be used to treat the fatal lung scarring disease idiopathic pulmonary fibrosis (IPF).
Expert insights. Personalized for you.
116 
Let's personalize your content